<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933517</url>
  </required_header>
  <id_info>
    <org_study_id>Getna7/CJP1.0</org_study_id>
    <nct_id>NCT00933517</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy of the Neoadjuvant Combination: &quot;Chemotherapy-Targeted Therapy&quot; in Breast Cancer.</brief_title>
  <acronym>TVA</acronym>
  <official_title>Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pathological response rate in operable breast&#xD;
      cancer patients treated by neoadjuvant combination: &quot;FEC-Taxotere/Vectibix&quot;.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the rate of complete histological response, according to Chevallier's classification</measure>
    <time_frame>after 24 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of complete histological response, according to Sataloff's classification; the rate of clinical, ultrasound, mammogram response, according to the WHO criteria; progression-free and overall survival; the tolerance.</measure>
    <time_frame>After 24 weeks of treatment, at surgery and at five years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">62</enrollment>
  <condition>Pathological Response Rate</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vectibix</intervention_name>
    <description>9mg/kg at D1 of each 21-days cycle</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracile</intervention_name>
    <description>500 mg/m2 at D1 of each 21-days cycle</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicine</intervention_name>
    <description>100 mg/m2 at D1 of each 21-days cycle</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>500 mg/m2 at D1 of each 21 dyas cycle</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>100 mg/m2 at D1 of each 21 days cycle</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ³ 18.- Performance status £ 2 (according to WHO criteria).&#xD;
&#xD;
          -  Patient has histologically confirmed, non-metastatic breast cancer, with a clinical&#xD;
             tumour diameter of ³ 2 cm&#xD;
&#xD;
          -  HR negative and Her-2 negative.&#xD;
&#xD;
          -  Clinical stage II and IIIa.&#xD;
&#xD;
          -  Patients not previously treated by surgery, radiotherapy, hormone therapy or&#xD;
             chemotherapy.· Haematology: o Neutrophil count ≥1.5x109/Lo Platelet count ≥100x109/Lo&#xD;
             Leucocyte count &gt; 3,000/mmo Hb&gt; 9g/dl· Hepatic Function:o Total bilirubin ≤ 1.5 time&#xD;
             the upper normal limit (UNL)o ASAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL&#xD;
             in presence of liver metastases ALAT ≤ 2.5xUNL in absence of liver metastases, or&#xD;
             ≤5xUNL in presence of liver metastases Alkaline phosphatase ≤ 2.5 time the upper&#xD;
             normal limit (UNL)· Renal Function· Creatinine clearance ≥50 mL/min and serum&#xD;
             creatinine ≤1.5xUNL· Metabolic Function o Magnesium ≥ lower limit of normal. o Calcium&#xD;
             ≥ lower limit of normal.&#xD;
&#xD;
          -  Patient with no progressive heart disease, and for whom anthracyclines are not&#xD;
             contraindicated (normal FEV).&#xD;
&#xD;
          -  Patient has signed the consent forms for participation before inclusion in the trial.&#xD;
&#xD;
          -  Member of a Social Security scheme (or a beneficiary of such a scheme) according to&#xD;
             the provisions of the law of 9 August 2004.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male patients.&#xD;
&#xD;
          -  Her-2 positive patients&#xD;
&#xD;
          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment.&#xD;
&#xD;
          -  Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for 6 months (male or&#xD;
             female) after the end of treatment.&#xD;
&#xD;
          -  Any form of breast cancer other than those described in the inclusion criteria,&#xD;
             particularly inflammatory and/or overlooked forms (T4b or T4d).&#xD;
&#xD;
          -  Non-measurable tumour.&#xD;
&#xD;
          -  Patients have already undergone surgery for their disease or have had primary axillary&#xD;
             dissection.&#xD;
&#xD;
          -  Patient has already been treated for new breast cancer.&#xD;
&#xD;
          -  Patient is a ward.&#xD;
&#xD;
          -  Patient has a history of second cancer, with exception of in situ cervical cancer or&#xD;
             basocellular skin cancer which is regarded as cured.&#xD;
&#xD;
          -  Patient has another disease which is deemed incompatible with the patient being&#xD;
             included in the protocol.&#xD;
&#xD;
          -  Heart or kidney failure, medullary, respiratory or liver failure.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) £ 1 year before enrollment/randomization&#xD;
&#xD;
          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan&#xD;
&#xD;
          -  Significant neurological or psychiatric abnormalities.&#xD;
&#xD;
          -  Symptomatic or progressive disorder of the central nervous system (CNS) or metastasis&#xD;
             at the initial check-up.&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 2 (NCI-CTCAE criteria, Version 3.0).&#xD;
&#xD;
          -  History of allergy to polysorbate 80.&#xD;
&#xD;
          -  Concomitant treatment with a trial drug, participation in another clinical trial&#xD;
             within &lt; 30 days or previous chemotherapy.&#xD;
&#xD;
          -  Patient with no fixed address in the next 6 months or living at a distance from the&#xD;
             treatment centre so it is difficult to check her progress.&#xD;
&#xD;
          -  Prior anti-EGFr antibody therapy (e.g.:cetuximab) or treatment with small molecule&#xD;
             EGFr tyrosine kinase inhibitors (e.g.: erlotinib).&#xD;
&#xD;
          -  Known previous or ongoing abuse of narcotic drug, other medication or alcohol.&#xD;
&#xD;
          -  Any investigational agent within 30 days before initiation of study treatment. - Must&#xD;
             not have had a major surgical procedure within 28 days of initiation of treatment.&#xD;
&#xD;
          -  Subject unwilling or unable to comply with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pole Santé République</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Montluçon</city>
        <zip>03113</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>July 3, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer, neoadjuvant therapies, chemotherapy, targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

